Chronic Hepatitis D Infection

Infectious Diseases
4
Pipeline Programs
2
Companies
6
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
1
2
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
3100%
+ 5 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Mirum Pharmaceuticals
Mirum PharmaceuticalsFOSTER CITY, CA
3 programs
1
2
Brelovitug 300 mgPhase 31 trial
Brelovitug 300 mgPhase 31 trial
Brelovitug 300 mgPhase 2/31 trial
Active Trials
NCT06907290Active Not Recruiting150Est. Sep 2029
NCT07298330Recruiting80Est. Jan 2029
NCT07200908Recruiting172Est. Sep 2029
GS
Gilead SciencesFOSTER CITY, CA
5 programs
1
BulevirtidePhase 1Peptide1 trial
Anti DeltaN/A1 trial
Anti DeltaN/A
BulevirtideN/APeptide
BulevirtideN/APeptide1 trial
Active Trials
NCT06248580Recruiting20,000Est. Mar 2025
NCT05718700Active Not Recruiting170Est. Jul 2028
NCT05760300Completed41Est. Jul 2024

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
2027
2028
2029
Mirum PharmaceuticalsBrelovitug 300 mg
Mirum PharmaceuticalsBrelovitug 300 mg
Mirum PharmaceuticalsBrelovitug 300 mg
Gilead SciencesBulevirtide
Gilead SciencesAnti Delta
Gilead SciencesBulevirtide

Clinical Trials (6)

Total enrollment: 20,613 patients across 6 trials

NCT07298330Mirum PharmaceuticalsBrelovitug 300 mg

A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)

Start: Jan 2026Est. completion: Jan 202980 patients
Phase 3Recruiting
NCT07200908Mirum PharmaceuticalsBrelovitug 300 mg

A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)

Start: Aug 2025Est. completion: Sep 2029172 patients
Phase 3Recruiting
NCT06907290Mirum PharmaceuticalsBrelovitug 300 mg

A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection

Start: Mar 2025Est. completion: Sep 2029150 patients
Phase 2/3Active Not Recruiting
NCT05760300Gilead SciencesBulevirtide

A Multiple-Dose Study of Bulevirtide in Participants With Normal and Impaired Renal Function

Start: Mar 2023Est. completion: Jul 202441 patients
Phase 1Completed
NCT06248580Gilead SciencesAnti Delta

Find HDV and Determine Its Status in Turkey

Start: Mar 2024Est. completion: Mar 202520,000 patients
N/ARecruiting
NCT05718700Gilead SciencesBulevirtide

Study of Bulevirtide in Participants With Chronic Hepatitis D Infection

Start: Feb 2023Est. completion: Jul 2028170 patients
N/AActive Not Recruiting

Related Jobs in Infectious Diseases

Director, Program Management

Metaphore Biotechnologies
Somerville, MA USA
9h ago
$179K - $237K/yr

Consultor Técnico Vacinas Adulto (Brasília/DF)

GSK
BRA - Distrito Federal - Brasília
22h ago

Production Supervisor/First Line Leader

GSK
USA - North Carolina - Zebulon
22h ago

Community Engagement Account Manager - New Haven

GSK
USA - Connecticut - New Haven
22h ago

Scientist, Protein Purification

GSK
USA - Massachusetts - Cambridge
22h ago
$90K - $150K/yr

Scientist, Protein Biochemistry

GSK
USA - Massachusetts - Cambridge
22h ago
$90K - $150K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
3 actively recruiting trials targeting 20,613 patients
2 companies competing in this space

Related Indications

HIV Infections(449)COVID-19(223)Hepatitis C(191)Influenza(173)HIV(138)HIV-1-infection(115)Hepatitis C, Chronic(94)Chronic Hepatitis B(93)Chronic Hepatitis C(91)Covid19(79)